Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
New England Journal of MedicinePublished 27 October 2010
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki
Citations4,455
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.
Abstract
The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
American Journal of Clinical OncologyToxicity and response criteria of the Eastern Cooperative Oncology Group
11,623 Citations1982Martin M. Oken, Richard H. Creech +5 more
The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
New England Journal of MedicineActivating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
11,503 Citations2004Thomas J. Lynch, Daphne W. Bell +12 more
A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Science<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
9,415 Citations2004J. Guillermo Paez, Pasi A. Jänne +15 more
Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
New England Journal of MedicineGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
8,249 Citations2009Tony Mok, Yi‐Long Wu +17 more
Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
NatureIdentification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
5,416 Citations2007Manabu Soda, Young Lim Choi +16 more
It is shown that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.
Proceedings of the National Academy of SciencesEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
4,344 Citations2004William Pao, Vincent A. Miller +13 more
Data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.
Journal of Clinical OncologyClinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>
1,882 Citations2009Alice T. Shaw, Beow Y. Yeap +16 more
EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics and patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.
NatureIdentification of ALK as a major familial neuroblastoma predisposition gene
1,387 Citations2008Yaël P. Mossé, Marci Laudenslager +20 more
It is demonstrated that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal paediatric malignancy.
Clinical Cancer Research<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
983 Citations2008Jussi Koivunen, Craig H. Mermel +19 more
EML4-ALK was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers, and TAE684 inhibited the growth of one of three EML4-alk-containing cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis.
NatureActivating mutations in ALK provide a therapeutic target in neuroblastoma
892 Citations2008Rani E. George, Takaomi Sanda +19 more
Journal of Clinical OncologyFirst-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations
834 Citations2008Lecia V. Sequist, Renato Martins +17 more
First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance, and should be compared with combination chemotherapy.
CancerThe <i>EML4‐ALK</i> fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type <i>EGFR</i> and <i>KRAS</i>
722 Citations2009Daisy Wing‐Sze Wong, Elaine Lai‐Han Leung +8 more
The authors of this study investigated the frequency, genetic and clinicopathologic profiles of EML4‐ALK in Chinese patients with NSCLC to identify the fusion gene resulting from the chromosome inversion inv(2)(p21;p23).
Clinical Cancer ResearchKIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
712 Citations2009Kengo Takeuchi, Young Lim Choi +12 more
An intercalated antibody-enhanced polymer (iAEP) method that incorporates an intercalating antibody between the primary antibody to ALK and the dextran polymer-based detection reagents should prove suitable for immunohistochemical screening of tumors positive for ALK or ALK fusion proteins among pathologic archives.
Clinical Cancer ResearchUnique Clinicopathologic Features Characterize <i>ALK</i> -Rearranged Lung Adenocarcinoma in the Western Population
682 Citations2009Scott J. Rodig, Mari Mino–Kenudson +13 more
Lung adenocarcinomas with ALK rearrangements are uncommon in the western population and represent a distinct entity of carcinomas with unique characteristics, and dual diagnostic testing, with FISH and immunohistochemistry, should be considered.
Molecular Cancer TherapeuticsCytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
647 Citations2007James G. Christensen, Helen Y. Zou +8 more
A strong correlation was observed between antitumor response and inhibition of N PM-ALK phosphorylation and induction of apoptosis in tumor tissue, illustrating the potential clinical utility of inhibitors of NPM-ALK in treatment of patients with ALK-positive ALCL.
Journal of Clinical OncologyProspective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
505 Citations2006Akira Inoue, Takuji Suzuki +7 more
Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity, and a subsequent randomized trial comparing gefITinib with standard chemotherapy is warranted.
Clinical Cancer ResearchMultiplex Reverse Transcription-PCR Screening for <i>EML4-ALK</i> Fusion Transcripts
504 Citations2008Kengo Takeuchi, Young Lim Choi +12 more
A multiplex reverse transcription-PCR system is developed that captures all in-frame fusions between EML4 to exon 20 of ALK to reinforce the importance of accurate diagnosis of E ML4-ALK–positive tumors for the optimization of treatment strategies.
Cancer ResearchIdentification of Novel Isoforms of the <i>EML4-ALK</i> Transforming Gene in Non–Small Cell Lung Cancer
438 Citations2008Young Lim Choi, Kengo Takeuchi +16 more
Two slightly different fusion cDNAs in which exon 6 of EML4 was joined to exon 20 of ALK were each identified in two individuals of the cohort and exhibited marked transforming activity in vitro as well as oncogenic activity in vivo.
Clinical Cancer ResearchA Novel, Highly Sensitive Antibody Allows for the Routine Detection of <i>ALK</i> -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
424 Citations2010Mari Mino–Kenudson, Lucian R. Chirieac +9 more
A novel, highly sensitive IHC assay reliably detects lung adenocarcinomas with ALK rearrangements and obviates the need for fluorescence in situ hybridization analysis for the majority of cases, and therefore could be routinely applicable in clinical practice to detect lung cancers that may be responsive to ALK inhibitors.
Cancer ResearchGenomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
403 Citations2008Ultan McDermott, A. John Iafrate +14 more
Findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clinically responsive to pharmacologic ALK inhibition.
British Journal of CancerA phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
278 Citations2006Hajime Asahina, K Yamazaki +12 more
This study showed that gefitinib is very active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations.
NeoplasiaEML4-ALK Fusion Lung Cancer: A Rare Acquired Event
247 Citations2008Sven Perner, Patrick Wagner +13 more
There is evidence that other, more common mechanisms besides gene inversion exist including the possibility of other fusion partners for ALK and EML4, and the NKX2-1 high-level amplification was confirmed in a significant subset of NSCLC and found this amplification to be mutually exclusive to ALk and E ML4 rearrangements.
Cancer ScienceNon‐solid oncogenes in solid tumors: <i> EML4–ALK</i> fusion genes in lung cancer
229 Citations2008Hiroyuki Mano
How detection of EML4–ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are positive for the fusion gene is summarized, and whether suppression of ALK enzymatic activity could be an effective treatment strategy against this intractable disorder is discussed.
Journal of Clinical OncologyClinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
205 Citations2009E.L. Kwak, D. Ross Camidge +8 more
Journal of Clinical OncologyMeta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
181 Citations2009Massimo Di Maïo, Paolo Chiodini +10 more
Doublet chemotherapy as second-line treatment of advanced NSCLC significantly increases response rate and progression-free survival, but is more toxic and does not improve overall survival compared to single-agent.
Cellular and Molecular Life SciencesOncogenic protein tyrosine kinases
138 Citations2004Karen Pulford, Laurence Lamant +6 more
The study of ALK fusion proteins has raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies, given that ALK fusions also occur in the mesenchymal tumor known as inflammatory myofibroblastic tumor (IMT).
Journal of Clinical OncologyMolecular Biology of Anaplastic Lymphoma Kinase–Positive Anaplastic Large-Cell Lymphoma
125 Citations2002Jeffery L. Kutok, Jon C. Aster
The unique molecular pathogenesis of ALK+ ALCL is likely to lead to novel therapeutic approaches directed at specific inhibition ofALK or downstream effectors, including ALK- ALCLs.
Journal of Thoracic OncologySecond-Line Treatment of Advanced Non-small Cell Lung Cancer
67 Citations2008Cesare Gridelli, Andrea Ardizzoni +11 more
Single-agent chemotherapy with docetaxel or pemetrexed is the recommended option for unselected patients with performance status 0 to 2 who are candidates for second-line chemotherapy for advanced non-small cell lung cancer and in selected patients such as lifetime nonsmokers or those of East-Asian ethnicity, erlotinib, or gefitinib may be considered as second-liners even if they are fit for chemotherapy.